Hints and tips:
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...(FT) Japan Inc goes global for M&A advice Only three domestic brokerages rank among the top-ten deal advisers in Japan during the third quarter. Why is Japan Inc looking for foreign advice?...
...The catalyst to the company’s legal challenge to these data extraction requests was a New York case last year involving an alleged drug dealer....
...New York-listed shares of Israeli drugmaker Teva Pharmaceuticals rose more than 1 per cent to $64.16, after the company offered to buy US drugmaker Mylan....
...The surge of deals came as executives, investors and bankers gathered in San Francisco for this week’s JPMorgan healthcare conference — the industry’s biggest annual get-together and traditionally a big catalyst...
...They argued that the next catalyst for the group’s share price would be the outcome of the so-called “Marianne” trial, which is expected in the third quarter and tests the efficacy of treating breast cancer...
...She also hopes that the art fair will serve as a catalyst for discussion about modernising India’s often disappointing museums and encourage the display of private collections in places such as Coimbatore...
...“Steady margin expansion will help drive free cash flow and in turn valuation and performance,” said James Sawtell, analyst. Citigroup also rated the stock a “buy”....
...He seeks catalysts to unlock value, such as corporate restructurings, spin-offs and share buybacks....
...Shire Pharmaceuticals was also in demand, rising 0.5 per cent to 876½p after US regulators approved Daytrana, a patch to treat attention deficit disorder....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
...Shire Pharmaceuticals appeared to be winning over market sceptics who initially reacted negatively when it announced plans to buy Transkaryotic Therapies, the US biotechnology company, for £840m in April...
...The company bolstered its reserves by much more than analysts had expected, and James Schiro, chief executive, said he expected no further additions....
International Edition